"503A" and "503B" are sections of the federal Food, Drug, and Cosmetic Act — the framework Congress clarified with the Drug Quality and Security Act of 2013 after the 2012 meningitis outbreak traced to a compounding pharmacy. Both describe legitimate compounders. They differ in who they answer to, what they can make without a prescription, and whether you can keep their products as office stock.
503A: the traditional compounding pharmacy
A 503A pharmacy compounds a medication for an individual patient against a specific prescription. This is the classic "the doctor wrote it, the pharmacy made it for this one patient" model.
- Overseen primarily by state boards of pharmacy, following USP compounding standards (USP <795> for non-sterile, <797> for sterile).
- Not required to register with the FDA as an outsourcing facility and not held to full drug-manufacturing cGMP.
- Compounds in response to patient-specific prescriptions; office-use (non-patient-specific) compounding is limited and varies by state.
- Best for customized formulations — a specific testosterone concentration, a combination injectable, a tailored peptide blend.
503B: the FDA-registered outsourcing facility
A 503B outsourcing facility is a category created specifically so clinics and hospitals could buy compounded medications as office stock — without a prescription for each patient.
- Voluntarily registers with the FDA and is inspected on a risk-based schedule.
- Must follow cGMP — the same current good manufacturing practice standards that govern drug manufacturers.
- Can compound in larger batches without patient-specific prescriptions, which is what makes office stock possible.
- Best for the in-office injectables you administer from the shelf rather than dispense to a named patient.
503A vs 503B at a glance
| 503A Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Primary oversight | State board of pharmacy | FDA (registers & inspects) |
| Manufacturing standard | USP <795> / <797> | Full cGMP |
| Patient-specific Rx required | Yes | No |
| Office stock (non-patient-specific) | Limited / state-dependent | Yes — its core purpose |
| Batch size | Small, per-prescription | Larger batches |
| Typical clinic use | Custom patient formulations | In-office injectable stock |
Which one does a TRT, peptide, or GLP-1 clinic use?
In practice, most cash-pay specialty clinics use both. You lean on a 503A pharmacy when a patient needs a customized compound — a non-standard testosterone concentration, a combination injectable, a peptide formulation written for that person. You lean on a 503B outsourcing facility for the injectables you keep on the shelf and administer in the office, where buying per-patient scripts would be impractical.
Compounded GLP-1s like semaglutide are a good example: a 503A pharmacy can compound against a specific patient prescription, while a 503B facility can supply office stock — and which route makes sense depends on whether you dispense or administer, plus the current FDA guidance and shortage status for that drug.
The operational catch: using both means two supplier relationships, two ordering workflows, and two sets of lot numbers and expiration dates to track — on top of the DEA recordkeeping any controlled substance already demands. That tracking burden is where most clinics' spreadsheets break down.
What this means for your EHR and inventory
The 503A/503B split isn't just a procurement detail — it's a documentation obligation. Whatever you administer or dispense, you need to know the exact lot, the expiration date, the quantity remaining, and which patient received which lot, in a record that holds up to a board or DEA audit.
This is exactly what Moonshot Clinic was built to handle. It supports multiple suppliers across both 503A and 503B facilities, tracks inventory at the lot level with first-expired-first-out dispensing, deducts down to the milligram when a medication is charted, and keeps an immutable transaction trail for DEA-ready reporting — and compounded orders can be placed right from the patient chart.
- DEA-compliant inventory tracking — lot-level, mg-level, FEFO, immutable audit trail
- E-prescribing & compounded ordering — order from the chart, no separate login
- EHR for peptide clinics and GLP-1 weight-loss clinics
This guide is general information for clinic operators, not legal, regulatory, or pharmacy-compliance advice. FDA guidance on compounding — especially for drugs like GLP-1s tied to shortage lists — changes over time. Confirm current requirements with your pharmacy partners, your state board, and qualified counsel before making procurement or clinical decisions.